Trial reportAmerican journal of hematology2021
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Open access · greenAbstract readClinical TrialLetter
In one paragraph
Trial report in American journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 28 citations in OpenAlex.
- STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026Review
- Pyrimethamine Restores KEAP1-Mediated Degradation of Select NRF2 Mutants in Esophageal Squamous Cell Carcinoma.Cancers · 2026Article
- IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia.HemaSphere · 2026Article
- STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASCancer science · 2025Article
- Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway.Oncology research · 2025Article
- The role of IL-22 in cancer.Medical oncology (Northwood, London, England) · 2024Review
- C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration.Journal of translational medicine · 2024Article
- Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.Cancers · 2024Review
- Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.Cancers · 2024Review
- Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.Journal of experimental & clinical cancer research : CR · 2024Review
- Article
- Pyrimethamine reduced tumour growth in pre-clinical cancer models: a systematic review to identify potential pre-clinical studies for subsequent human clinical trials.Biology methods & protocols · 2024Review
- Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.Nutrients · 2023Article
- Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials.Cancers · 2023Review
- Eupalinolide J Inhibits Cancer Metastasis by Promoting STAT3 Ubiquitin-Dependent Degradation.Molecules (Basel, Switzerland) · 2023Article
- Discovery of new STAT3 inhibitors as anticancer agents using ligand-receptor contact fingerprints and docking-augmented machine learning.RSC advances · 2023Article
- Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity.Metabolites · 2023Article
- Application of Drug Repurposing-Based Precision Medicine Platform for Leukaemia Patient Treatment.Advances in experimental medicine and biology · 2023Review
- Review
- Pyrimethamine inhibits cell growth by inducing cell senescence and boosting CD8Molecular biology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Jennifer R BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Sarah R WalkerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Lisa N HepplerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Svitlana TyekuchevaDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Erik A NelsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Josephine KlitgaardDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Maria NicolaisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Yasmin KrollDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Michael XiangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Jennifer E YehDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Mousumi ChaudhuryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Zachary T GiacconeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Stacey M FernandesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Eric D JacobsenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
David C FisherDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Arnold S FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0002-8227-8916
Matthew S DavidsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Jeffrey G SupkoDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Catherine WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
David A FrankDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0002-7698-8364
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USHarvard University · US
Funding
Unlocking the Potential of PI3K Inhibition in CLLR01CA213442 · NCI · DANA-FARBER CANCER INST · PI BROWN, JENNIFER R · 2017 to 2021
$2.9MDual STAT3/NF-kB Inhibitors for Targeted Cancer TherapyR01CA160979 · NCI · DANA-FARBER CANCER INST · PI FRANK, DAVID A. · 2012 to 2016
$1.8MNCI NIH HHS R01 CA160979NCI NIH HHS R01 CA213442
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic AgentsB-LymphocytesCell Line, TumorDose-Response Relationship, DrugDrug RepositioningDrug Screening Assays, AntitumorFemaleGene Expression ProfilingGene Expression Regulation, LeukemicHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedAntineoplastic AgentsNeoplasm ProteinsPyrimethamineSTAT3 protein, humanSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.